Sci Rep:静脉癌栓肾细胞癌患者的基因组特性分析

2018-05-19 AlexYang MedSci原创

静脉癌栓(VTT)肾细胞癌(RCC)潜在的致死的并发症,但是其潜在的自然发生历史却了解很少。最近,有研究人员观察到静脉血栓包含了数量可观的可视肿瘤细胞,他们利用多区域全外显子组测序手段对37名原发肿瘤和VTT样本,同时包括了来自5名连续性患者的正常组织样本。研究发现,原发肿瘤和VTT之间的变异异质性存在483个相关基因中的106个(22%),这些基因在原发肿瘤或者血栓中要么存在SNVs,要么存在插

静脉癌栓(VTT)肾细胞癌(RCC)潜在的致死的并发症,但是其潜在的自然发生历史却了解很少。最近,有研究人员观察到静脉血栓包含了数量可观的可视肿瘤细胞,他们利用多区域全外显子组测序手段对37名原发肿瘤和VTT样本,同时包括了来自5名连续性患者的正常组织样本。

研究发现,原发肿瘤和VTT之间的变异异质性存在483个相关基因中的106个(22%),这些基因在原发肿瘤或者血栓中要么存在SNVs,要么存在插入或者缺失变异。无性系重建建展示了肿瘤样本和VTT样本在大多数肿瘤中的聚类情况。然而,研究人员没有检测到新的亚克隆,表明了先前存在的原发肿瘤亚克隆能够促使VTT的形成。重要的是,研究人员发现了在一类肿瘤中发现了 "BRCAness" 的一系列证据。这些证据包括了基因中能够确定 "BRCAness" 的变异情况,即变异特性方面和小的插入缺失的增加。从TCGA KIRC-US群体中的SNV重分析确定了 "BRCAness"变异特性AC3在透明细胞RCC中高频率存在。

最后,研究人员指出,他们的发现促进了进一步的预临床试验,并且也许能够促使产生RCC患者的新的个性化疗法。

原始出处:

Gregor Warsow, Daniel Hübschmann, Kortine Kleinheinz et al. Genomic features of renal cell carcinoma with venous tumor thrombus. Sci Rep. 10 May 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978681, encodeId=7cde19e86813b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Jan 10 00:06:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697697, encodeId=bfda169e6971b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Jan 17 12:06:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800010, encodeId=cc1418000106a, content=<a href='/topic/show?id=fd1ce1299b2' target=_blank style='color:#2F92EE;'>#癌栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71299, encryptionId=fd1ce1299b2, topicName=癌栓)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Sat Jan 26 12:06:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317275, encodeId=b93f31e275fc, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 21 20:38:52 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316859, encodeId=fc1f31685951, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun May 20 08:05:24 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316645, encodeId=d0dd316645f5, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat May 19 15:11:20 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1978681, encodeId=7cde19e86813b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Jan 10 00:06:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697697, encodeId=bfda169e6971b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Jan 17 12:06:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800010, encodeId=cc1418000106a, content=<a href='/topic/show?id=fd1ce1299b2' target=_blank style='color:#2F92EE;'>#癌栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71299, encryptionId=fd1ce1299b2, topicName=癌栓)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Sat Jan 26 12:06:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317275, encodeId=b93f31e275fc, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 21 20:38:52 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316859, encodeId=fc1f31685951, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun May 20 08:05:24 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316645, encodeId=d0dd316645f5, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat May 19 15:11:20 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2019-01-17 fusion
  3. [GetPortalCommentsPageByObjectIdResponse(id=1978681, encodeId=7cde19e86813b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Jan 10 00:06:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697697, encodeId=bfda169e6971b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Jan 17 12:06:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800010, encodeId=cc1418000106a, content=<a href='/topic/show?id=fd1ce1299b2' target=_blank style='color:#2F92EE;'>#癌栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71299, encryptionId=fd1ce1299b2, topicName=癌栓)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Sat Jan 26 12:06:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317275, encodeId=b93f31e275fc, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 21 20:38:52 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316859, encodeId=fc1f31685951, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun May 20 08:05:24 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316645, encodeId=d0dd316645f5, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat May 19 15:11:20 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1978681, encodeId=7cde19e86813b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Jan 10 00:06:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697697, encodeId=bfda169e6971b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Jan 17 12:06:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800010, encodeId=cc1418000106a, content=<a href='/topic/show?id=fd1ce1299b2' target=_blank style='color:#2F92EE;'>#癌栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71299, encryptionId=fd1ce1299b2, topicName=癌栓)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Sat Jan 26 12:06:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317275, encodeId=b93f31e275fc, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 21 20:38:52 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316859, encodeId=fc1f31685951, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun May 20 08:05:24 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316645, encodeId=d0dd316645f5, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat May 19 15:11:20 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-21 changjiu

    学习一下谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1978681, encodeId=7cde19e86813b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Jan 10 00:06:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697697, encodeId=bfda169e6971b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Jan 17 12:06:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800010, encodeId=cc1418000106a, content=<a href='/topic/show?id=fd1ce1299b2' target=_blank style='color:#2F92EE;'>#癌栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71299, encryptionId=fd1ce1299b2, topicName=癌栓)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Sat Jan 26 12:06:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317275, encodeId=b93f31e275fc, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 21 20:38:52 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316859, encodeId=fc1f31685951, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun May 20 08:05:24 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316645, encodeId=d0dd316645f5, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat May 19 15:11:20 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-20 kafei

    学习学习谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1978681, encodeId=7cde19e86813b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Jan 10 00:06:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697697, encodeId=bfda169e6971b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Jan 17 12:06:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800010, encodeId=cc1418000106a, content=<a href='/topic/show?id=fd1ce1299b2' target=_blank style='color:#2F92EE;'>#癌栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71299, encryptionId=fd1ce1299b2, topicName=癌栓)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/fa8I6JticHgohY5FSGE98I1F4gpCjrpl2nbN6jZJY6JEqAjUibjItOA9AsgbBwTuBzAPbU5Tl8DxfemWUFFzBOYw/132, createdBy=24c12500054, createdName=ms2186806800017884, createdTime=Sat Jan 26 12:06:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317275, encodeId=b93f31e275fc, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon May 21 20:38:52 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316859, encodeId=fc1f31685951, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun May 20 08:05:24 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316645, encodeId=d0dd316645f5, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat May 19 15:11:20 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-19 天地飞扬

    了解一下.谢谢分享!

    0

相关资讯

tivozanib治疗索拉非尼治疗后晚期肾细胞癌患者的疗效:III期交叉研究

Tivozanib是血管内皮生长因子受体1、2和3酪氨酸激酶的选择性抑制剂。这项开放标签交叉临床研究(AV-951-09-902)研究了tivozanib在索拉非尼治疗的II期临床试验TIVO-1中疾病仍有进展的患者中的疗效,比较了tivozanib和索拉非尼治疗晚期肾细胞癌(RCC)患者的有效性及安全性。

Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案(Alliance A031203 CABOSUN随机试验):总生存期和无进展生存

随机II期CABOSUN试验比较了cabozantinib和舒尼替尼作为中等或低风险晚期肾细胞癌(RCC)的初始治疗方案,主要终点为符合研究者预期的无进展生存期(PFS)的改善。研究者通过独立的放射学审查委员会(IRC)评估报告PFS、ORR和总体生存期(OS)。先前未经治疗的患有IMDC标准的中度或低风险RCC患者,随机分为1:1至卡唑替尼60 mg / d或舒尼替尼50 mg / d

Brit J Cancer:透明细胞转移性肾细胞癌中,转移性和原发肿瘤基因组背景研究

原发透明细胞肾细胞癌(ccRCC)的基因组背景已经有详细的阐释。然而,关于群体基因组变异(GA)背景在ccRCC转移中的情况所知甚少,或者说与原发性肿瘤在总体上的基因组背景差异情况。研究人员认为,转移性肿瘤的基因组背景也许具有生物学、临床和治疗应用。研究主要运用了二代测序技术。群体1(n=578)包括了348个原发性肿瘤案例和229个转移性肿瘤案例。总的来讲,转移性肿瘤中最为常见的变异为VHL (

CLIN CANCER RES:Pembrolizumab联合聚乙二醇干扰素或Ipilimumab治疗晚期黑色素瘤或肾细胞癌

Pembrolizumab单药,Ipilimumab单药或聚乙二醇干扰素(PEG-IFN)单药对黑色素瘤和肾细胞癌均有抗肿瘤活性。CLIN CANCER RES近期发表了一篇文章,研究Pembrolizumab联合Ipilimumab或PEG-IFN对晚期黑色素瘤或肾细胞癌的抗肿瘤活性。

Brit J Cancer:在晚期肾细胞癌中,卡博替尼和依维莫司药物治疗的总生存长期跟踪调查研究

在阶段3 METEOR试验中(NCT01865747)的抗血管生成治疗之后,与依维莫司药物相比,卡博替尼在晚期肾细胞癌(RCC)患者中能够显著提高无进展自由生存、总生存和客观反映率。在320例记录死亡的第二个中间分析中,研究人员观察到了在总生存方面的显著提升。最近,有研究人员将患有晚期RCC的658名且至少接受1种VEGFR 酪氨酸激酶抑制剂治疗的患者随机分成2个小组,即卡博替尼组(60mg每天)

Sci Rep:利用基因表达对透明细胞肾细胞癌的个性化药物重新定位研究

癌症基因表达的逆转能够预测治疗方法的潜力,并且可以为已经存在的药物发现新的应用方法(药物重新定位)。基因表达逆转潜力在几乎所有的研究中都进行了估算,方法是通过预先将所有肿瘤样本聚集到单一组标签中或者有限的几个分子亚型组标签中。最近,有研究人员调查了是否基于个性化的肿瘤样本基因表达特征的药物重新定位能够优于肿瘤组和亚型组标签药物的使用。研究人员利用来自于530名透明细胞肾细胞癌(ccRCC)患者的5